CN104968650A - 奥普佐米(Oprozomib)的调节释放制剂 - Google Patents

奥普佐米(Oprozomib)的调节释放制剂 Download PDF

Info

Publication number
CN104968650A
CN104968650A CN201380067772.0A CN201380067772A CN104968650A CN 104968650 A CN104968650 A CN 104968650A CN 201380067772 A CN201380067772 A CN 201380067772A CN 104968650 A CN104968650 A CN 104968650A
Authority
CN
China
Prior art keywords
acceptable salt
preparation
puzuo
meter
opzomib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380067772.0A
Other languages
English (en)
Chinese (zh)
Inventor
默罕奈德.裘马
东尼.木查米尔
奈文.拜裘甘
汪汉森
克里斯多福.J.科克
R.V.曼克
S.莎马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Therapeutics Inc
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CN104968650A publication Critical patent/CN104968650A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380067772.0A 2012-10-24 2013-10-24 奥普佐米(Oprozomib)的调节释放制剂 Pending CN104968650A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261717975P 2012-10-24 2012-10-24
US61/717975 2012-10-24
US201261721244P 2012-11-01 2012-11-01
US61/721244 2012-11-01
US201361793087P 2013-03-15 2013-03-15
US61/793087 2013-03-15
PCT/US2013/066679 WO2014066681A1 (en) 2012-10-24 2013-10-24 Modified release formulations for oprozomib

Publications (1)

Publication Number Publication Date
CN104968650A true CN104968650A (zh) 2015-10-07

Family

ID=50485877

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380067772.0A Pending CN104968650A (zh) 2012-10-24 2013-10-24 奥普佐米(Oprozomib)的调节释放制剂

Country Status (24)

Country Link
US (2) US9295708B2 (enExample)
EP (1) EP2912025A4 (enExample)
JP (1) JP6505604B2 (enExample)
KR (1) KR20150070406A (enExample)
CN (1) CN104968650A (enExample)
AP (1) AP3681A (enExample)
AR (1) AR093126A1 (enExample)
AU (1) AU2013334258A1 (enExample)
BR (1) BR112015008572A2 (enExample)
CA (1) CA2888039A1 (enExample)
CL (1) CL2015001085A1 (enExample)
CR (1) CR20150266A (enExample)
EA (1) EA201590797A1 (enExample)
HK (2) HK1208222A1 (enExample)
IL (1) IL238244A0 (enExample)
IN (1) IN2015DN03921A (enExample)
MX (1) MX2015005069A (enExample)
PE (1) PE20151051A1 (enExample)
PH (1) PH12015500823A1 (enExample)
SG (1) SG11201502849XA (enExample)
TN (1) TN2015000135A1 (enExample)
TW (1) TW201422255A (enExample)
UY (1) UY35091A (enExample)
WO (1) WO2014066681A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
CN110357940A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 奥普佐米合成工艺研究

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2016204939A1 (en) * 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
AU2017290147B2 (en) * 2016-06-29 2021-09-09 Kezar Life Sciences Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
US20180078532A1 (en) 2016-09-21 2018-03-22 Amgen Inc. Immediate release formulations for oprozomib
US20180161279A1 (en) * 2016-12-14 2018-06-14 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
CN111108125A (zh) 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
KR20250008774A (ko) 2022-05-11 2025-01-15 셀진 코포레이션 T 세포 요법 및 그의 생산과 관련된 방법 및 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105786A1 (en) * 2005-11-09 2007-05-10 Proteolix, Inc. Compounds for enzyme inhibition
CN1972678A (zh) * 2004-04-30 2007-05-30 阿勒根公司 延长缓释超过2个月的类固醇眼内植入物
US20100240903A1 (en) * 2009-03-20 2010-09-23 Onyx Therapeutics, Inc. Crystalline tripeptide epoxy ketone protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
DE60221642T3 (de) * 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
JP5124286B2 (ja) * 2006-01-10 2013-01-23 キッセイ薬品工業株式会社 徐放性製剤およびその製造方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
JP5734656B2 (ja) * 2007-10-04 2015-06-17 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1972678A (zh) * 2004-04-30 2007-05-30 阿勒根公司 延长缓释超过2个月的类固醇眼内植入物
US8263110B2 (en) * 2004-04-30 2012-09-11 Allergan, Inc. Sustained release intraocular implants and related methods
US20070105786A1 (en) * 2005-11-09 2007-05-10 Proteolix, Inc. Compounds for enzyme inhibition
US20100240903A1 (en) * 2009-03-20 2010-09-23 Onyx Therapeutics, Inc. Crystalline tripeptide epoxy ketone protease inhibitors
US20120077855A1 (en) * 2009-03-20 2012-03-29 Pasit Phiasivongsa Crystalline tripeptide epoxy ketone protease inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALI NOKHODCHI ET AL: "The effect of various surfactants on the release rate of propranolol hydrochloride from hydroxypropylmethylcellulose (HPMC)-Eudragit matrices", 《EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS》 *
DFE PHARMA: "Lactose Some basic properties and characteristics", 《DFE PHARMA》 *
DOW: "Using Dow Excipients for controlled Release of drug in hydrophilic matrix systems", 《DOW》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
CN110357940A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 奥普佐米合成工艺研究

Also Published As

Publication number Publication date
KR20150070406A (ko) 2015-06-24
EA201590797A1 (ru) 2016-02-29
MX2015005069A (es) 2015-07-17
AP3681A (en) 2016-04-19
IN2015DN03921A (enExample) 2015-10-02
TW201422255A (zh) 2014-06-16
CA2888039A1 (en) 2014-05-01
HK1208222A1 (en) 2016-02-26
AU2013334258A1 (en) 2015-04-30
PE20151051A1 (es) 2015-08-03
IL238244A0 (en) 2015-06-30
US20160213610A1 (en) 2016-07-28
EP2912025A1 (en) 2015-09-02
EP2912025A4 (en) 2016-06-08
AP2015008387A0 (en) 2015-04-30
CR20150266A (es) 2015-08-14
SG11201502849XA (en) 2015-05-28
US9295708B2 (en) 2016-03-29
JP6505604B2 (ja) 2019-04-24
PH12015500823A1 (en) 2015-06-22
HK1215709A1 (zh) 2016-09-09
US20140113855A1 (en) 2014-04-24
BR112015008572A2 (pt) 2017-07-04
AR093126A1 (es) 2015-05-20
UY35091A (es) 2014-05-30
WO2014066681A1 (en) 2014-05-01
CL2015001085A1 (es) 2015-08-28
JP2015535255A (ja) 2015-12-10
TN2015000135A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
JP6505604B2 (ja) オプロゾミブの放出調節製剤
US9949932B2 (en) Formulation of syk inhibitors
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
US20230203009A1 (en) Pralsetinib pharmaceutical compositions
JP2025506374A (ja) インターロイキン－２３受容体のペプチド阻害剤及びその医薬組成物
JP6680297B2 (ja) 経口投与用医薬組成物
JP2023184662A (ja) イストラデフィリン製剤
US20180078532A1 (en) Immediate release formulations for oprozomib
TW201836593A (zh) 奧普佐米之胃滯留改良釋放之劑型及其製備方法
ES2454197T3 (es) Formas polimórficas de Irbesartán
JP7820568B2 (ja) 溶出性及び打錠性に優れた製剤
JP2026505072A (ja) インターロイキン－２３受容体の結晶性ペプチド阻害剤を調製するための方法
TW202333702A (zh) 具有優異溶出性之醫藥組成物
HK40117634A (zh) 白介素-23受体的肽抑制剂及其药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215709

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151007

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215709

Country of ref document: HK